- Login
- Register & Subscribe
- Language: EN FR DE
Belgium
United Kingdom
Switzerland
France-based Cellectis SA has acquired a new partner for its portfolio of products for cancer that are based on donor T cells that have been engineered to target specific antigen on cancer cells. The allogeneic portfolio had been licensed to Pfizer Inc and Servier.
France
United Kingdom
United States
United Kingdom
United States
Japan’s Takeda Pharmaceutical Company Ltd has announced plans to acquire the Belgium-based cell therapy company TiGenix NV for €520 million, a company with which it already has a licensing deal for the company’s lead product.
Belgium
United States
Tuesday April 24 2018
Tuesday April 24 2018
Tuesday April 24 2018
Tuesday April 24 2018
Tuesday April 24 2018